AstraZeneca (NASDAQ:AZN) and Mustang Bio (NASDAQ:MBIO) Head-To-Head Contrast

Mustang Bio (NASDAQ:MBIO) and AstraZeneca (NASDAQ:AZN) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, earnings, risk, dividends, analyst recommendations, institutional ownership and valuation.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Mustang Bio and AstraZeneca, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mustang Bio	1	0	0	0	1.00
AstraZeneca	1	0	9	0	2.80

AstraZeneca has a consensus target price of $95.75, suggesting a potential downside of 54.13%. Given AstraZeneca’s stronger consensus rating and higher possible upside, analysts plainly believe AstraZeneca is more favorable than Mustang Bio.

Valuation and Earnings

This table compares Mustang Bio and AstraZeneca”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mustang Bio	N/A	N/A	-$15.75 million	($0.31)	-3.26
AstraZeneca	$58.74 billion	5.51	$7.04 billion	$5.80	35.99

AstraZeneca has higher revenue and earnings than Mustang Bio. Mustang Bio is trading at a lower price-to-earnings ratio than AstraZeneca, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

10.0% of Mustang Bio shares are held by institutional investors. Comparatively, 20.4% of AstraZeneca shares are held by institutional investors. 4.0% of Mustang Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Volatility and Risk

Mustang Bio has a beta of 2.14, suggesting that its share price is 114% more volatile than the S&P 500. Comparatively, AstraZeneca has a beta of 0.34, suggesting that its share price is 66% less volatile than the S&P 500.

Profitability

This table compares Mustang Bio and AstraZeneca’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Mustang Bio	N/A	-75.33%	-16.50%
AstraZeneca	16.17%	32.89%	13.00%

Summary

AstraZeneca beats Mustang Bio on 11 of the 13 factors compared between the two stocks.

About Mustang Bio

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-117 and MB-217, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-101 CAR T cell program for glioblastoma; MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.